CLINICAL_TRIALS ClinicalTrials.gov record with results posted

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03656536
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-08-12T00:02:10.274756+00:00
Published At: 2026-08-11T00:00:00+00:00
Record Updated At: 2026-08-11
Results Posted At: 2026-08-11
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Unresectable Cholangiocarcinoma", "Metastatic Cholangiocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-08-11"
protocolSection.identificationModule.nctId: "NCT03656536"
protocolSection.identificationModule.officialTitle: "A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2026-08-11"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.